Individual Comparative PK Evaluation of Single-dose Octocog Alfa, Rurioctocog Alfa Pegol, and Efanesoctocog Alfa in Adults with Severe Hemophilia A
Open Access
- 9 January 2026
- journal article
- Published by Georg Thieme Verlag KG in TH Open
- Vol. 10 (CP)
Abstract
No abstract availableFunding Information
- Sanofi
This publication has 19 references indexed in Scilit:
- Classification of recombinant factor VIII products and implications for clinical practice: A systematic literature reviewHaemophilia, 2024
- Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfaResearch and Practice in Thrombosis and Haemostasis, 2023
- Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia ANew England Journal of Medicine, 2023
- Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factorJournal of Thrombosis and Haemostasis, 2023
- Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic ReviewClinical Pharmacokinetics, 2021
- Limited sampling strategies for accurate determination of extended half‐life factor VIII pharmacokinetics in severe haemophilia A patientsHaemophilia, 2021
- BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia ANew England Journal of Medicine, 2020
- WFH Guidelines for the Management of Hemophilia, 3rd editionHaemophilia, 2020
- Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophiliaHaemophilia, 2020
- The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII.Journal of Biological Chemistry, 1991